Medicus Pharma (NASDAQ:MDCX) Stock Gets Downgrade from Brookline Capital Markets

Medicus Pharma (NASDAQ:MDCX) was downgraded by stock analysts at Brookline Capital Markets from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday, FinViz reports.

Several other analysts have also issued reports on the company. Weiss Ratings raised Medicus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 30th. Wall Street Zen downgraded Medicus Pharma from a “sell” rating to a “strong sell” rating in a research note on Sunday. Finally, Alliance Global Partners reaffirmed a “buy” rating on shares of Medicus Pharma in a research note on Monday, September 14th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $450.00.

Medicus Pharma Price Performance

NASDAQ:MDCX traded down $0.12 during trading hours on Wednesday, reaching $1.71. 32,793 shares of the company were exchanged, compared to its average volume of 82,472. The company has a market capitalization of $2.15 million, a P/E ratio of -0.02 and a beta of 0.80. Medicus Pharma has a 1-year low of $1.68 and a 1-year high of $127.50. The business has a 50 day moving average of $5.69 and a 200 day moving average of $21.07.

Medicus Pharma (NASDAQ:MDCX) last posted its quarterly earnings data on Friday, November 6th. The company reported ($11.64) EPS for the quarter, missing analysts’ consensus estimates of ($8.50) by ($3.14). As a group, equities research analysts anticipate that Medicus Pharma will post -33.50 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Medicus Pharma

Several hedge funds and other institutional investors have recently modified their holdings of MDCX. Sterling Investment Advisors Ltd. bought a new stake in shares of Medicus Pharma during the 2nd quarter worth $45,000. Private Advisor Group LLC acquired a new position in Medicus Pharma during the 3rd quarter worth approximately $37,000. Finally, Interchange Capital Partners LLC increased its position in Medicus Pharma by 33.9% during the 3rd quarter. Interchange Capital Partners LLC now owns 2,124,910 shares of the company’s stock worth $343,000 after purchasing an additional 538,039 shares in the last quarter.

Medicus Pharma Company Profile

Medicus Pharma Ltd. (NASDAQ:MDCX) is a life sciences company focused on acquiring, developing and commercializing pharmaceutical and medical products. The company seeks to identify therapies and healthcare technologies with potential for commercialization and works to advance them through regulatory, clinical and market-development processes. Medicus Pharma’s activities are centered on specialty healthcare markets, including pharmaceutical and medical products designed to address unmet patient and provider needs.